CJC-1295 with DAC vs Rapamycin
Well Studied vs FDA Approved
monitor Mechanism-based · 47% Both CJC-1295 with DAC and Rapamycin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
CJC-1295 with DAC Rapamycin
Weight 3,647.28 Da 914.17 Da
Half-life 6-8 days ~62 hours
Chain 30 amino acids —
Type GHRH analog with DAC Macrolide lactone (C51H79NO13)
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Rapamycin
01 Lifespan extension demonstrated in every model organism tested (yeast, worms, flies, mice)
02 Upregulation of autophagy and cellular quality control mechanisms
03 Reduction of senescent cell burden and associated inflammatory secretome
04 Improved immune function at low pulsed doses (paradoxical immune enhancement)
05 Reduced age-related inflammation (inflammaging) via mTORC1 inhibition
06 Enhanced mitochondrial function and biogenesis
07 Potential reduction in age-related cancer risk through growth pathway suppression
08 Improved vaccine response in elderly populations at low intermittent doses
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Rapamycin
3-6 mg once weekly (longevity protocol) / Once weekly (pulsed longevity) or daily (immunosuppressive)
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Rapamycin
Mouth sores / aphthous ulcers (most common, usually dose-dependent and self-limiting)
Mild lipid changes (elevated LDL cholesterol and triglycerides)
Temporary glucose elevation or mildly impaired fasting glucose
Mild gastrointestinal discomfort (nausea, loose stools)
Skin changes (mild acne, slower wound healing at injection/cut sites)
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Active serious infection or immunocompromised state
Hypersensitivity to rapamycin/sirolimus or any macrolide compound
Severe hepatic impairment (rapamycin is extensively hepatically metabolized)
Planned major surgery within 2-4 weeks (impaired wound healing)
Pregnancy or breastfeeding
Concurrent use of strong CYP3A4 inhibitors without dose adjustment (ketoconazole, itraconazole, clarithromycin, grapefruit juice)
Research Evidence
CJC-1295 with DAC Rapamycin
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest 2025 March 2023
FDA Approved No Yes
Full CJC-1295 with DAC profile Full Rapamycin profile CJC-1295 with DAC calculator Rapamycin calculator
More comparisons: Metformin
This comparison is for educational and research purposes only. Consult a healthcare professional before use.